Rain Therapeutics

Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rain Oncology is a clinical-stage company focusing on research and development of innovative therapies for cancer patients.  Rain Oncology provides a tumor-agnostic strategy to select patients based on tumors’ underlying genetics rather than histology.  Rain Oncology was founded in 2017 and was headquartered in Newark, California.

NEWARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the pricing of its initial public offering of 7,352,941 shares of common stock at a public offering price of $17.00 per share. The gross proceeds to Rain from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Rain, are expected to be approximately $125.0 million. All of the shares are being offered by Rain. The shares are expected to begin trading on The Nasdaq Global Select Market on April 23, 2021 under the ticker symbol “RAIN.” In addition, Rain has granted the underwriters a 30-day option to purchase up to an additional 1,102,941 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 27, 2021 subject to the satisfaction of customary closing conditions.

Rain Therapeutics Announces Pricing of Initial Public Offering

News for Rain Therapeutics Stock (RAIN)